NEW YORK (GenomeWeb News) – Arno Therapeutics today announced it has inked an exclusive, worldwide licensing deal with the University of Minnesota for a technology covering a gene expression signature derived from archived breast cancer tissue samples.

As part of the deal, Arno will continue development of a progesterone receptor gene signature as a potential companion diagnostic for anti-progestins, including Arno's lead compound called onapristone for treating men's and women's cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.